Results 151 to 160 of about 677,625 (318)

Prescribing of Medication to Prevent Glucocorticoid Harms in Patients With Polymyalgia Rheumatica: A Cross‐Sectional Study and Two Emulated Target Trials in the Clinical Practice Research Datalink Aurum

Arthritis &Rheumatology, EarlyView.
Objective Polymyalgia rheumatica (PMR) is a common indication for long‐term glucocorticoid (GC) treatment. Bone‐protective and gastroprotective medications are recommended for those at high risk of adverse events from GCs, but no trials have evaluated their effectiveness in PMR.
Helen Twohig, David Jenkinson, James Bailey, Samantha Hider, Ian C. Scott, Sara Muller   +5 more
wiley   +1 more source

Efficacy and safety of eptinezumab in adults with chronic migraine and medication-overuse headache who also received patient education: 24-week results of the randomized RESOLUTION trial. [PDF]

J Headache Pain
Schytz HW, Jensen RH, Lundqvist C, Tassorelli C, Vernieri F, Lantéri-Minet M, Terwindt GM, Blumenfeld A, Tepper SJ, Josiassen MK, Jansson G, Ettrup A, Mittoux A, Lipton RB.   +13 more
europepmc   +1 more source

Evaluating the Potential Infectious Risk Profile of Biologics in Chronic Rhinosinusitis With Nasal Polyposis

International Forum of Allergy &Rhinology, EarlyView.
Maxime Fieux, Philippe Gevaert, Leigh J. Sowerby   +2 more
wiley   +1 more source

Anifrolumab Treatment Leads to Rapid Reduction in Urinary Biomarkers of Intrarenal Inflammation in Lupus Nephritis: Results From the Phase 2 Randomized Trial

Arthritis &Rheumatology, EarlyView.
Objective Lupus nephritis (LN) is one of the most severe manifestations of systemic lupus erythematosus (SLE) and is partially driven by type I interferon signaling. Anifrolumab, an approved treatment for patients with SLE, has been investigated in a phase 2 trial in patients with LN receiving standard therapy (TULIP‐LN, ClinicalTrials.gov identifier ...
Andrea Fava, Michelle Petri, Patrick G. Gavin, Eszter Csomor, Philip Z. Brohawn, Daniel Muthas, Adam Platt, Catharina Lindholm, Nicola Ferrari   +8 more
wiley   +1 more source

Pro-cognitive effects of 5-HT4 receptor agonism in individuals with remitted depression. [PDF]

Psychol Med
de Cates AN, Hamilton S, Guru A, Blandhol M, Colwell M, Cowen PJ, Simmons M, Jones B, Harmer CJ, Murphy SE.   +9 more
europepmc   +1 more source

Treatment of a Large Cohort of Childhood Chronic Noninfectious Uveitis in a Multicentric Large Study: Adalimumab Versus Methotrexate as First‐Line Therapy

Arthritis &Rheumatology, EarlyView.
Objective Treatment of childhood chronic idiopathic uveitis (cCIU) is predominantly based on studies in juvenile idiopathic arthritis–associated uveitis and expert opinion. Our aim was to report the treatment outcomes of our cohort of cCIU. Methods Retrospective multicenter study involving the rheumatology and ophthalmology units at Florence, Italy ...
Ilaria Maccora, Catherine Guly, Cinzia de Libero, Giulia Carreras, Athimalaipet V. Ramanan, Gabriele Simonini   +5 more
wiley   +1 more source

Effects of carnosine supplementation on physical endurance: a placebo-controlled randomized clinical trial. [PDF]

J Int Soc Sports Nutr
O'Toole TE, Wingard CJ, Bariess SK, Crandell CE, Amraotkar AR, Gao H, Bhatnagar A.   +6 more
europepmc   +1 more source

Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week‐24 Results of a Phase 3, Randomized, Placebo‐Controlled Study

Arthritis &Rheumatology, EarlyView.
Objective To evaluate the efficacy and safety of guselkumab, an interleukin‐23p19 subunit inhibitor, in participants with active psoriatic arthritis (PsA) and inadequate response (inadequate efficacy and/or intolerance) to one prior tumor necrosis factor (TNF) inhibitor.
Alexis Ogdie, Joseph F. Merola, Philip J. Mease, Christopher T. Ritchlin, Jose U. Scher, Kimberly Parnell Lafferty, Daphne Chan, Soumya D. Chakravarty, Wayne Langholff, Yanli Wang, Jie Shao, Yevgeniy Krol, Alice B. Gottlieb   +12 more
wiley   +1 more source

Phase 3 PERSPECTIVE study: Ibrutinib with rituximab for initial treatment of patients with follicular lymphoma. [PDF]

Hemasphere
Belada D, Gardner FP, de Oliveira AC, Sancho JM, Lomaia E, Wright D, Turgut M, Martynova E, Lázár Z, Anz B, Wang MC, Legiec W, Opat S, Pailden J, Peltier HM, Marturano E, Dean JP, Flinn IW.   +17 more
europepmc   +1 more source

Manipulating reading skills using the placebo effect: description of the research project.

openL’obiettivo di questo elaborato è quello di descrivere un progetto di ricerca, finalizzato a indagare la presenza di effetti placebo e nocebo sulle abilità di lettura di studenti universitari.
DEMONTE, ELENA
core